Probiotics in gastroenteritis in children: A systematic review
Abstract
Background and objectives: Gastroenteritis is the second leading cause of death among children worldwide. It is a preventable and treatable disease, yet it affects 3 to 5 million children and is the cause of approximately 10% of hospitalizations globally. This systematic review aims to identify the effectiveness of probiotics in treating acute gastroenteritis in children globally and also to provide results of quality research to healthcare-related communities about possible therapies of the condition.
Methods: This study follows the PRISMA guidelines for systematic reviews of 29 quantitative studies conducted between 2014-2023. A quality appraisal of the selected studies was conducted using CADIMA and a rating scale of 0 to 3 based on a few predetermined criteria.
Results: Sample sizes varied from 29 to 1811, with a median of 200. Globally, there are mixed findings about the roles and benefits of probiotics to treat acute gastroenteritis in children. This is possibly due to the type of probiotic, the type of disease, and treatment adherence.
Conclusions: Findings from this systematic review suggest that probiotics play a crucial role in improving children’s health outcomes. Therefore, it is important to promote and implement the use of probiotic therapies in the treatment of acute gastroenteritis conditions in children.
IMC J Med Sci. 2023; 17(2):010. DOI: https://doi.org/10.55010/imcjms.17.020
*Correspondence: Amal K. Mitra, Department of Epidemiology & Biostatistics,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.